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The precise cellular characteristics of retinoblastoma have long been debated. In this issue of Cancer Cell,
McEvoy et al. reveal that retinoblastomas are highly homogeneous at the molecular level and coexpress
genes characteristic of retinal progenitors and various different mature retinal cell types, while ultrastructur-
ally resembling amacrine cells.Both the cellular characteristics and the
cell of origin of retinoblastoma have been
hotly disputed (Nichols et al., 2009). Pri-
mary retinoblastomas not only express
genes characteristic of retinal progenitor
cells, but also multiple different terminally
differentiated retina cell types, including
rod and cone photoreceptors, retinal in-
terneurons, and glia. The gene expression
profiles of all major retinal cell types have
been characterized (Blackshaw et al.,
2004; Trimarchi et al., 2008), and it should
be possible to clarify the molecular char-
acteristics and perhaps even the cell of
origin of retinoblastoma using similar ap-
proaches. While the early postnatal pre-
sentation of retinoblastoma suggests that
it may arise as a result of mutations in
mitotic retinal progenitor cells, a pair of
recent studies has suggested retinoblas-
tomas can develop from postmitotic hori-
zontal interneurons and cone photorecep-
tors (Ajioka et al., 2007; Xu et al., 2009).
Profiling gene expression in multiple sam-
ples may resolve this confusion. Further-
more, a clear and comprehensive picture
of the gene expression profile of retino-
blastomas could help considerably in the
design of supplemental treatments for
patients who do not respond to conven-
tional surgical and chemotherapy-based
treatments.
In this issue of Cancer Cell, McEvoy
et al. (2011) have undertaken this task
with aplomb and come up with some
surprising findings. By conducting micro-
array analysis of 52 primary retinoblas-
toma tumors obtained from patients and
120 tumors obtained from six different
lines of mutant mice that spontaneously
develop retinoblastoma, they found that
the gene expression patterns of tumorsfrom both humans and mice were very
similar. The vast majority of tumors coex-
pressed markers of retinal progenitors,
rod and cone photoreceptors, and both
amacrine and horizontal interneurons,
echoing results from a smaller previous
survey of retinoblastoma gene expression
(Ganguly and Shields, 2010). They next
assessed the gene expression profile of
20 different isolated single cells obtained
from xenografts of a human primary reti-
noblastoma. Remarkably, the gene ex-
pression profiles of individual cells closely
mirrored those of the whole tumor, con-
firming that virtually every published study
on the molecular characteristics of reti-
noblastoma is at least partially correct.
Remarkably, however, retinoblastomas
turned out to be highly homogenous at
the cellular level, and uniformly coex-
pressed genes that are normally com-
pletely specific to various different retinal
cell subtypes.
Which retinal cell typedo these ‘‘hybrid’’
cells most closely resemble? To address
this question, McEvoy et al. (2011) har-
nessed the power of electron microscopy
to extract ten diagnostic morphological
parameters for themajor retinal cell types.
Applying these criteria, they reported that
retinoblastomas most closely resemble
the amacrine cells, while the presence of
large dense core synaptic vesicles sug-
gests that they resemble one of the rare
monoaminergic subtypes. These ultra-
structural studies further confirmed the re-
lative cellular homogeneity of the tumors,
with no cells showing either the apical
cilia or outer segments that are charac-
teristic of rod and cone photoreceptors.
The authors conclude their study with
a powerful demonstration of the potentialCancer Cell 20clinical relevance of their encyclopedic
analysis of the molecular and ultrastruc-
tural anatomy of retinoblastoma. Since
retinoblastomas express genes charac-
teristic of monoaminergic amacrine cells,
they tested the effect of chlorpromazine
and fluphenazine, which are broad-spec-
trum neuroleptic compounds that block
both dopamine and serotonin receptors
and are normally used in treatment of
schizophrenia and bipolar disorder, and
found that these effectively inhibited
tumor growth (Figure 1).
This work is a technical tour de force,
and sheds unexpected light on several
different questions in both oncology and
developmental biology. The fact that
retinoblastoma cells robustly coexpress
genes that are characteristic of at least
four different mature retinal cell types, in
addition to retinal progenitors, does not
directly implicate any one of these cells
as the source of the tumor (Figure 1).
However, one notable exception comes
from the tumors of Rb+/; p107/;
p130/ mice, which have been previ-
ously reported to give rise to retinoblas-
toma through dedifferentiation of hori-
zontal cells (Ajioka et al., 2007). The
expression profile of these tumors much
more closely resembled that of horizontal
and amacrine cells than did that of other
retinoblastomas. The cell of origin may
thus indeed be atypical for this genotype,
with the vast majority of tumors arising
from another source, most likely retinal
progenitor cells.
The two neuroleptic drugs shown to
be effective in inhibiting tumor growth
are unusually broad spectrum, antago-
nizing dopamine, serotonin, and adren-
ergic receptors. More specific receptor, August 16, 2011 ª2011 Elsevier Inc. 137
Figure 1. A New View of Retinoblastoma
Retinoblastoma cells morphologically resemble amacrine cells but simulta-
neously coexpress genes specific to horizontal and amacrine interneurons,
rod and cone photoreceptor, and retinal progenitors.
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tumor growth. Previous stud-
ies have implicated serotonin
in this role in a number of
other tumor types, although
this has not been reported
for neuroectodermal tumors
such as retinoblastoma. This
may imply that multiple
monoamines act synergisti-
cally as autocrine mitogens
for retinoblastoma cells, a
hypothesis supported by the
authors’ finding that retino-
blastomas secrete a range of
different monoamines. How-
ever, they did not show that
monoamines directly pro-
mote tumor growth, and it
is thus possible that these
drugs may act on unexpected
target sites. The finding that
antipsychotic drugs may
inhibit the growth of a broad
range of tumors by inhibiting
cholesterol metabolism (Wi-
klund et al., 2010) may prove
informative in this respect.While this does not diminish the potential
clinical usefulness of these compounds
in treating retinoblastoma, much more
work needs to be done to clarify their
mechanism of action.
The finding that retinoblastoma cells
robustly coexpress gene characteristic
has potentially far-reaching implications
for developmental neurobiology. The con-
trol of cell fate specification is ultimately
a process of establishing mutually exclu-
sive, cell-specific patterns of transcrip-
tion. Hundreds of different genes have
been identified that regulate the process
of cell fate specification, but these gener-
ally act to direct a cell to adopt one fate in
preference to another, or to drive differen-
tiation from a less to a more differentiated
state. Loss of function of a handful of tran-
scription factors and coregulators has
been previously found to result in hybrid
retinal cell types, but these findings
come with some important qualifications.
Such mutant cells coexpress genes from138 Cancer Cell 20, August 16, 2011 ª2011 Eonly two cell types, such as rod and
cone photoreceptors, which are closely
functionally related in any case, with only
a subset of cell-specific genes misregu-
lated (Swaroop et al., 2010). In contrast,
retinoblastoma cells appear to express
a full complement of genes characteristic
of at least four terminally differentiated
retinal cell types, as well as mitotic retinal
progenitors. This data points to a central
and general role of Rb family proteins in
repressing inappropriate expression of
cell type-specific genes.
What exactly is going on, andwhat rele-
vance might it have to the question of the
retinoblastoma cell of origin? The fact that
retinoblastomas do not express markers
of the bipolar interneurons and Muller
glia—two last-born retinal cell types—
offers one potential clue. This result is
consistent with a model where loss of
function of Rb family proteins in early-
stage retinal progenitors might both pre-
vent cell cycle exit and also compromiselsevier Inc.repression of terminal mark-
ers of early-born cell types.
Clues to how this might hap-
pen are provided by the find-
ing that Rb acts in mesen-
chymal stem cells to regulate
cell fate specification by di-
rectly binding and modulating
the activity of developmen-
tally important transcription
factors (Calo et al., 2010).
Further analysis of the targets
of Rb family proteins will shed
light on whether and how they




Ajioka, I., Martins, R.A., Bayazitov,
I.T., Donovan, S., Johnson, D.A.,
Frase, S., Cicero, S.A., Boyd, K.,
Zakharenko, S.S., and Dyer, M.A.
(2007). Cell 131, 378–390.
Blackshaw, S., Harpavat, S., Tri-
marchi, J., Cai, L., Huang, H., Kuo,
W.P., Weber, G., Lee, K., Fraioli,
R.E., Cho, S.H., et al. (2004). PLoS
Biol. 2, E247.Calo, E., Quintero-Estades, J.A., Danielian, P.S.,
Nedelcu, S., Berman, S.D., and Lees, J.A. (2010).
Nature 466, 1110–1114.
Ganguly, A., and Shields, C.L. (2010). Mol. Vis. 16,
1292–1303.
McEvoy, J., Flores-Otero, J., Zhang, J., Nemeth,
K., Brennan, R., Bradley, C., Krafcik, F.,
Rodriguez-Galindo, C., Wilson, M., Xiong, S.,
et al. (2011). Cancer Cell 20, this issue, 260–275.
Nichols, K.E., Walther, S., Chao, E., Shields, C.,
and Ganguly, A. (2009). Curr. Opin. Ophthalmol.
20, 351–355.
Swaroop, A., Kim, D., and Forrest, D. (2010). Nat.
Rev. Neurosci. 11, 563–576.
Trimarchi, J.M., Stadler, M.B., and Cepko, C.L.
(2008). PLoS ONE 3, e1588.
Wiklund, E.D., Catts, V.S., Catts, S.V., Ng, T.F.,
Whitaker, N.J., Brown, A.J., and Lutze-Mann,
L.H. (2010). Int. J. Cancer 126, 28–40.
Xu, X.L., Fang, Y., Lee, T.C., Forrest, D., Gregory-
Evans, C., Almeida, D., Liu, A., Jhanwar, S.C.,
Abramson, D.H., and Cobrinik, D. (2009). Cell
137, 1018–1031.
